The global inhaled nitric oxide market size reached US$ 943.7 Million in 2023. Looking forward, the publisher expects the market to reach US$ 1.65 billion by 2032, exhibiting a growth rate (CAGR) of 6.46% during 2023-2032.
Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.
Inhaled nitric oxide (iNO) refers to a selective pulmonary vasodilator supervised by skilled physicians at tertiary neonatal intensive care units (NICUs). It assists in regulating vascular muscle tone and treating hypoxemic respiratory failure among newly born infants by improving ventilation-perfusion mismatch and reducing elevated pulmonary vascular resistance and hypertension. It also aids in improving oxygenation and decreasing the need for extracorporeal membrane oxygenation (ECMO). At present, there is a rise in the use of iNO therapy as a rescue agent for acute respiratory distress syndrome (ARDS) patients.
Inhaled Nitric Oxide Market Trends:
The increasing prevalence of respiratory and other subsequent diseases in newborns, such as persistent pulmonary hypertension and neonatal hypoxic respiratory failure (HRF), represents one of the primary factors significantly contributing to the market growth. Additionally, the rising geriatric population, which is relatively more prone to hypertension, atherosclerosis, peripheral artery disease, heart failure, and thrombosis, is supporting the growth of the market. Furthermore, iNO is gaining immense traction worldwide for treating chronic obstructive pulmonary diseases (COPD), asthma, and ARDS.Moreover, the outbreak of the highly contagious coronavirus disease (COVID-19) and an alarmingly increasing number of individuals getting infected on a global level are favorably influencing the market. Furthermore, iNO therapy is being used against coronavirus stains as it assists in improving ventilation/perfusion in patients with severe pneumonia. The market is also driven by the ongoing research and development (R&D) activities in the healthcare industry around the world to improve the overall patient experience.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global inhaled nitric oxide market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application.Breakup by Application:
- Neonatal Respiratory Treatment
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Respiratory Distress Syndrome (ARDS)
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Air Liquide S.A, Bellerophon Therapeutics, Beyond Air Inc., Linde plc, Mallinckrodt plc, Merck KGaA, Novoteris LLC, Nu-Med Plus and VERO Biotech LLC.Key Questions Answered in This Report:
- How has the global inhaled nitric oxide market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global inhaled nitric oxide market?
- What are the key regional markets?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global inhaled nitric oxide market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary9 Value Chain Analysis11 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Inhaled Nitric Oxide Market
6 Market Breakup by Application
7 Market Breakup by Region
8 SWOT Analysis
10 Porters Five Forces Analysis
12 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Air Liquide S.A
- Bellerophon Therapeutics
- Beyond Air Inc.
- Linde plc
- Mallinckrodt plc
- Merck KGaA
- Novoteris LLC
- Nu-Med Plus
- VERO Biotech LLC.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 943.7 Million |
| Forecasted Market Value ( USD | $ 1650 Million |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
